The conflicting behavior of GSK-3β in GI cancers could be explained by the fact that GSK-3β inhibits the Wnt/β-catenin pathway—a major oncogenic driver in GC—and its expression is often reduced or inactivated in aggressive GC. The gene discussed is GSK3B; the disease is gastric cancer.